Table 2.
Group 1 | Group 2 | Group 3 | Group 4 | |
---|---|---|---|---|
N | 27 | 48 | 5 | 30 |
Age (years) | 62.95 ± 17.54 | 54.89 ± 16.03 | 77.77 ± 9.47 | 53.02 ± 18.31 |
Male (%) | 63 | 60 | 20 | 57 |
BSA (m2) | 2.14 ± 0.34 | 2.10 ± 0.27 | 1.97 ± 0.3 | 2.08 ± 0.42 |
Baseline HR (bpm) | 76.8 ± 20.7 | 75.2 ± 11.84 | 66.0 ± 9.2 | 67.74 ± 18.31 |
Time to echo (days) | 0.22 ± 1.09 | 0.23 ± 0.66 | 0.60 ± 0.89 | 0.53 ± 1.04 |
TRVmax (m/s) | 3.38 ± 0.42 | 2.42 ± 0.26 | 3.19 ± 0.19 | 2.11 ± 0.44 |
ePLAR (m/s) | 0.48 ± 0.08 | 0.42 ± 0.13 | 0.20 ± 0.08 | 0.20 ± 0.07 |
TAPSE (mm) | 18.17 ± 5.46 | 24.23 ± 6.57 | 18.25 ± 3.87 | 19.79 ± 6.43 |
S’(cm/s) | 12.68 ± 3.50 | 14.44 ± 3.95 | 12.00 ± 3.87 | 13.17 ± 2.85 |
Group 1 (Abnormal TRVmax, elevated ePLAR ≥ 0.28 m/s), Group 2 (normal TRVmax, elevated ePLAR ≥ 0.28 m/s), Group 3 (Abnormal TRVmax, normal ePLAR < 0.28 m/s), and Group 4 (normal TRVmax, normal ePLAR < 0.28 m/s).